Payment overview · 2025
General Payments
$738.35
33 reported records · 12 companies
Healthcare provider profile · identity verified
William Robert Sonnenberg, MD
Allopathic & Osteopathic Physicians|Family Medicine · TITUSVILLE, PA · NPI 1932173366
Verified facts
What the public records show
CMS Open Payments records show William Robert Sonnenberg, MD received $738.35 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Nurtec Odt, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 570 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.88 | 25.2% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.75 | 20.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.14 | 10.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.70 | 9.4% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $65.50 | 8.9% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $51.09 | 6.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.55 | 6.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.02 | 3.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.62 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.59 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.34 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.17 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $738.35 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $200.30 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.47 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.70 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $65.50 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.54 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.54 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $51.09 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.86 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 570 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
570 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 884 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 787 | 113 |
| Gabapentin | Gabapentin | 633 | 87 |
| Furosemide | Furosemide | 631 | 105 |
| Eliquis | Apixaban | 570 | 65 |
| Sertraline Hcl | Sertraline Hcl | 510 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 490 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 476 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 470 | 88 |
| Lisinopril | Lisinopril | 462 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 452 | 69 |
| Potassium Chloride | Potassium Chloride | 399 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 354 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 354 | 48 |
| Simvastatin | Simvastatin | 350 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 52 |
| Metformin Hcl | Metformin Hcl | 337 | 60 |
| Famotidine | Famotidine | 335 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 311 | 45 |
| Donepezil Hcl | Donepezil Hcl | 290 | 44 |
| Mirtazapine | Mirtazapine | 284 | 35 |
| Olanzapine | Olanzapine | 275 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 266 | 34 |
| Xarelto | Rivaroxaban | 260 | 31 |
| Omeprazole | Omeprazole | 255 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 237 | 48 |
| Losartan Potassium | Losartan Potassium | 234 | 35 |
| Lorazepam | Lorazepam | 216 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 215 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 212 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 210 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 193 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 191 | 24 |
| Levetiracetam | Levetiracetam | 175 | 23 |
| Trazodone Hcl | Trazodone Hcl | 174 | 33 |
| Memantine Hcl | Memantine Hcl | 165 | 25 |
| Bumetanide | Bumetanide | 160 | 23 |
| Valsartan | Valsartan | 159 | 23 |
| Allopurinol | Allopurinol | 156 | 28 |
| Atenolol | Atenolol | 149 | 21 |
| Buspirone Hcl | Buspirone Hcl | 149 | 19 |
| Carvedilol | Carvedilol | 133 | 21 |
| Spironolactone | Spironolactone | 132 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 131 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 118 | 28 |
| Aripiprazole | Aripiprazole | 116 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 15 |
| Baclofen | Baclofen | 103 | 13 |
| Risperidone | Risperidone | 101 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 93 | 15 |
| Finasteride | Finasteride | 89 | 12 |
| Montelukast Sodium | Montelukast Sodium | 85 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 84 | 15 |
| Tramadol Hcl | Tramadol Hcl | 84 | 21 |
| Clonazepam | Clonazepam | 83 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 12 |
| Farxiga | Dapagliflozin Propanediol | 79 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 18 |
| Divalproex Sodium | Divalproex Sodium | 76 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 23 |
| Entresto | Sacubitril/Valsartan | 67 | suppressed |
| Glimepiride | Glimepiride | 67 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 67 | 37 |
| Myrbetriq | Mirabegron | 67 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 46 |
| Meloxicam | Meloxicam | 65 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 65 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 26 |
| Haloperidol Lactate | Haloperidol Lactate | 64 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 62 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 15 |
| Prednisone | Prednisone | 62 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Cephalexin | Cephalexin | 59 | 27 |
| Pregabalin | Pregabalin | 59 | suppressed |
| Ozempic | Semaglutide | 58 | 13 |
| Glipizide | Glipizide | 55 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 13 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 50 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Folic Acid | Folic Acid | 46 | suppressed |
| Latanoprost | Latanoprost | 46 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 42 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 14 |
| Jardiance | Empagliflozin | 41 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 28 |
| Linzess | Linaclotide | 38 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 18 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Nyamyc | Nystatin | 32 | 18 |
| Haloperidol | Haloperidol | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Ursodiol | Ursodiol | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 28 | 21 |
| Ceftriaxone | Ceftriaxone Sodium | 27 | 12 |
| Lactulose | Lactulose | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 24 | 16 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Lacosamide | Lacosamide | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Nystatin | Nystatin | 22 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 22 | 13 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Nystop | Nystatin | 19 | 14 |
| Ziprasidone Hcl | Ziprasidone Hcl | 19 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | 11 |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Daptomycin | Daptomycin | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $738.35 · 33 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, MOUNJARO, NEXLETOL, NURTEC ODT, Ohtuvayre, PAXLOVID, REXULTI, TRELEGY ELLIPTA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error